What are the key challenges facing gene therapy commercialisation today, and how can the industry best overcome them? This Insight Article delves into the top 3 strategies needed to bring the next generation of advanced therapeutics to the market and get ahead of the game.

Arun Srivastava of the University of Florida’s takes us through the history of the AAV Vector development for Human Gene Therapy and analyses the critical role of his institution’s Division of Cellular and Molecular Therapy in the optimising and discovery of Next Generation AAVs.

Commentary piece following conversations with expert speakers from the Cell Series UK 2019

Dr. Vasiliki Kalodimou, Director at Flow Cytometry-Research & Regenerative Medicine Department, IASO Maternity & Research Hospital